查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2046574

龐貝氏症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按治療類型、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年

Pompe Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type, By Route of Administration, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球龐貝氏症治療市場預計將從 2025 年的 15.5 億美元成長到 2031 年的 20.2 億美元，複合年成長率為 4.51%。

這個市場主要集中於藥物療法，例如酵素替代療法和Chaperone療法，旨在糾正龐貝氏症（一種罕見的溶小體儲積症）相關的α-Glucosidase酶缺乏症。市場成長的主要促進因素包括全球新生兒篩檢計畫的擴展，這些計畫顯著提高了早期診斷率，並增加了對嬰兒期發病病例進行即時治療性介入的需求。支持孤兒藥認定的法規結構也是促進因素，為製藥公司提供了加速臨床開發和市場准入的經濟獎勵。然而，該市場面臨的主要挑戰是生物製藥終身治療費用極高。這可能會限制患者的用藥機會，並給全球醫療保健報銷體系帶來沉重負擔。此外，為如此小眾的患者群體開發先進治療方法的固有複雜性進一步加劇了這種經濟負擔。例如，2024 年，肌肉萎縮症協會投入約 3,600 萬美元，支持 150 多個研發項目，凸顯了持續資助以克服研發障礙和擴大神經肌肉疾病治療方案的必要性。

市場概覽
預測期 2027-2031
市場規模：2025年 15.5億美元
市場規模：2031年 20.2億美元
複合年成長率：2026-2031年 4.51%
成長最快的細分市場 酵素替代療法（ERT）
最大的市場 北美洲

市場促進因素

第二代酵素替代療法的進步正在改變全球龐貝氏症治療市場，有效解決了傳統生物製藥在療效和免疫抗原性方面所面臨的挑戰。這些旨在增強細胞攝取和改善肌肉組織內肝醣清除的新治療方法，正迅速受到新患者和從現有治療方法過渡到新療法患者的青睞。領先企業的強勁業績清晰地表明了這種向先進生物製藥的商業性轉變。例如，賽諾菲在2024年10月公佈，其第二代療法Nexviazyme的第三季銷售額達到1.63億歐元，年增53.6%，顯示患者正在顯著轉向更有效的治療方案。此外，具有全新作用機制的參與企業上市也推動了市場擴張。例如，Amicus Therapeutics在2024年11月公佈，其新推出的雙組分聯合治療Pomability和Opfolder的第三季全球銷售額達到2,110萬美元，凸顯了市場對新一代治療方法的強勁需求。強制性新生兒篩檢計畫的擴展是市場成長的關鍵促進因素，因為它能夠在無症狀性階段進行診斷並儘早啟動終身治療。鑑於嬰兒期發病的龐貝氏症進展迅速，將疾病納入公共衛生篩檢計畫至關重要，以便在生存所需的狹窄治療窗口期內識別患者，從而直接擴大目標市場。這項監管措施也在地方層級推廣，例如阿拉巴馬州公共衛生部於2024年7月正式實施新生兒龐貝氏症篩檢。這確保了受影響的嬰兒在出生後能夠立即被識別並及時轉診接受治療。這些舉措不僅改善了臨床結果，而且還建立了一個持續成長的患者群體，需要長期管理，從而確保了對治療性介入的長期需求。

市場挑戰

阻礙全球龐貝氏症治療市場成長的主要障礙在於終身生物製藥商業化帶來的高昂成本以及開發平臺的複雜性。這種沉重的經濟負擔是市場進入和擴張的重大障礙。在全球範圍內，醫療保險報銷體系往往會嚴格審查孤兒藥的高價，導致市場准入延遲和病患覆蓋範圍有限。酵素替代療法 (ERT) 和Chaperone療法的高昂成本對支付方的預算造成了壓力，需要嚴格的合格標準來限制目標患者群體，並直接降低了藥品生產商的潛在收入。此外，市場進展嚴重依賴持續的外部資金，以應對下一代治療方法高風險的研發階段。這種對持續資金注入的依賴使該行業面臨波動風險，非營利組織和產業投資的波動可能會導致關鍵研究停滯不前。例如，2025年12月，肌肉萎縮症協會撥款超過270萬美元，用於支持旨在開發神經肌肉疾病突破性治療方法的新研究津貼。雖然此類資金至關重要，但協會持續的財政支持對於降低臨床開發風險至關重要，這凸顯了研發生態系統的脆弱性，並阻礙了更有效的龐貝氏症新療法推向全球市場的速度。

市場趨勢

基材減少療法 (SRT) 的研究代表著一個重要的全新趨勢，它從根本上改變了治療模式，從單純清除體內累積的肝醣轉變為主動抑制其合成。與傳統的基材替代療法 (ERT) 不同，後者旨在分解現有的溶酶體糖原，而 SRT 透過小干擾 RNA (siRNA) 和小分子等機制抑製糖原合成酶 1 (GYS1)，從而減少肌肉組織中的肝醣生成。這是一種輔助治療策略，可用於控制疾病的代謝負擔，特別適用於 ERT 吸收不足的組織。為了佐證該方法的有效性，龐貝病新聞 (Pompe Disease News) 於 2025 年 9 月報導了ABX1100 的 1b 期臨床試驗完成情況，指出 Aro Biotherapeutics 公司的 SRT臨床實驗藥物 ABX1100 在僅兩次給藥後，就使肌肉樣本中的 GYS1 mRNA 水平降低了約 70%。同時，針對中樞神經系統（CNS）的藥物傳遞系統正日益受到市場關注。這旨在解決龐貝氏症的神經系統症狀，由於血腦障壁（BBB）的存在，傳統生物製藥無法有效治療這些症狀。隨著接受慢性酵素替代療法（ERT）的嬰兒期發病患者的生存期不斷延長，中樞神經系統病變已成為一項亟待解決的重大醫療需求，推動了新型治療方法的研發，例如專門設計用於主動穿過血腦屏障的融合蛋白和抗體-寡核苷酸偶聯物。各公司正利用其獨特的遞送平台，確保治療性酵素能夠到達神經細胞中的溶小體，這對於預防認知功能下降和神經運動功能障礙至關重要。作為該領域的一項進展，JCR Pharmaceuticals 在 2025 年 2 月發布的題為「在 2025 年 WORLDSymposium™ 展示研究成果」的新聞稿中宣布，該公司發布了一個新的資料集，證明其專有的 J-Brain Cargo 技術已成功將治療性酶輸送到血腦障壁，用於治療溶體。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：龐貝氏症治療的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療方法（藥物治療、酵素替代療法、物理治療、Chaperone/高級替代療法）
    • 給藥途徑（口服、注射）
    • 依最終使用者（醫院/專科診所、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美龐貝氏症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲龐貝氏症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區龐貝氏症治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲龐貝氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲龐貝氏症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球龐貝氏症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Genzyme Corporation
  • Amicus Therapeutics Inc
  • Valerion Therapeutics LLC
  • Audentes Therapeutics Inc
  • Actus Therapeutics Inc
  • BioMarin Pharmaceutical Inc
  • EpiVax inc
  • Oxyrane Co Ltd.
  • Sangamo BioSciences Inc
  • Avrobio Inc
  • Spark Therapeutics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17555

The Global Pompe Disease Therapeutics Market is projected to expand from USD 1.55 Billion in 2025 to USD 2.02 Billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 4.51%. This market primarily encompasses pharmacological treatments, such as Enzyme Replacement Therapies and chaperone treatments, which are designed to correct the deficiency of the acid alpha-glucosidase enzyme associated with Pompe disease, a rare lysosomal storage disorder. Key drivers for market growth include the worldwide expansion of mandatory newborn screening programs, which have significantly increased early diagnosis rates and the need for immediate therapeutic intervention in infantile-onset cases, as well as supportive regulatory frameworks that grant orphan drug designations, offering financial incentives for pharmaceutical companies to expedite clinical development and market entry.Challenges within this market, however, include the exceptionally high costs of lifelong biologic treatments, which can restrict patient access and place considerable strain on global healthcare reimbursement systems. This financial burden is exacerbated by the inherent complexities in developing advanced therapies for such a small patient population. For instance, in 2024, the Muscular Dystrophy Association allocated nearly 36 million dollars to support over 150 research and clinical projects, underscoring the vital need for continuous funding to overcome developmental obstacles and broaden the therapeutic options for neuromuscular conditions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.55 Billion
Market Size 2031USD 2.02 Billion
CAGR 2026-20314.51%
Fastest Growing SegmentEnzyme Replacement Therapy (ERT)
Largest MarketNorth America

Market Driver

Advancements in second-generation Enzyme Replacement Therapies are profoundly transforming the Global Pompe Disease Therapeutics Market by effectively addressing the limitations in efficacy and immunogenicity observed with earlier biologics. These newer therapies are engineered to enhance cellular uptake and improve glycogen clearance within muscle tissues, leading to their rapid adoption by both new patients and those transitioning from existing treatments. This commercial shift towards advanced biologics is well-demonstrated by the robust performance of leading companies, such as Sanofi, which reported in October 2024 a 53.6% year-over-year increase in third-quarter sales of its second-generation therapy, Nexviazyme, reaching €163 million, indicating a significant patient migration to more effective therapeutic options. Additionally, market expansion is supported by new competitors introducing therapies with novel mechanisms of action; Amicus Therapeutics, for example, reported in November 2024 that its newly launched dual-component therapy, Pombiliti and Opfolda, generated $21.1 million in global revenue during the third quarter, highlighting strong demand for next-generation treatment modalities.The expansion of mandatory newborn screening programs serves as a crucial driver for market volume by enabling presymptomatic diagnosis and the prompt initiation of lifelong therapy. Given the rapid progression of infantile-onset Pompe disease, integrating this condition into public health screening panels is essential for identifying patients within the narrow therapeutic window required for survival, thereby directly enlarging the addressable market. This regulatory momentum is gaining regional traction, as evidenced by the Alabama Department of Public Health's official implementation of Pompe disease screening for newborns in July 2024, ensuring that affected infants are identified and referred for treatment soon after birth. Such initiatives not only improve clinical prognoses but also establish a sustainable and growing patient pipeline requiring chronic management, thus securing long-term demand for therapeutic interventions.

Market Challenge

The primary obstacle hindering the growth of the Global Pompe Disease Therapeutics Market is the prohibitive cost structure associated with the commercialization of lifelong biologic treatments and the intricate nature of the research and development pipeline. This substantial financial burden creates significant barriers to market entry and expansion, as healthcare reimbursement systems globally increasingly scrutinize the high prices of orphan drugs, resulting in delayed market access and restricted patient coverage. The exorbitant expense of Enzyme Replacement Therapies (ERTs) and chaperone treatments strains payer budgets, necessitating strict eligibility criteria that limit the addressable patient population and directly diminish potential revenue for therapeutic manufacturers.Furthermore, the market's progress relies heavily on sustained external funding to navigate the high-risk developmental phases of next-generation therapies. This dependence on continuous capital infusion exposes the sector to volatility, where fluctuations in non-profit and industrial investment can stall critical research. For instance, in December 2025, the Muscular Dystrophy Association allocated over 2.7 million dollars to support new research grants aimed at neuromuscular disease breakthroughs. While such funding is crucial, the ongoing necessity for financial support from associations to de-risk clinical advancements underscores the fragility of the development ecosystem, impeding the speed at which new, more effective Pompe disease therapeutics can be introduced to the global market.

Market Trends

The investigation of substrate reduction therapeutic approaches represents a significant emerging trend, fundamentally shifting the treatment paradigm from merely clearing accumulated glycogen to actively preventing its synthesis. Unlike conventional enzyme replacement therapies (ERTs) that target the degradation of existing lysosomal glycogen, substrate reduction therapies (SRTs) utilize mechanisms such as small interfering RNA (siRNA) or small molecules to inhibit glycogen synthase 1 (GYS1), thereby reducing the production of glycogen in muscle tissue. This offers a complementary strategy for managing the disease's metabolic burden, especially in tissues where ERT uptake is inefficient. Validating this approach, Pompe Disease News reported in September 2025, in an article on the completion of the Phase 1b trial for ABX1100, that Aro Biotherapeutics' investigational SRT, ABX1100, demonstrated an approximately 70% reduction in GYS1 mRNA levels in muscle samples after just two infusions.Concurrently, the market is observing a pronounced focus on CNS-targeted drug delivery systems, aimed at addressing the neurological manifestations of Pompe disease that conventional biologics cannot treat due to the blood-brain barrier (BBB). As infantile-onset patients experience prolonged survival with chronic ERT, central nervous system involvement has become a critical unmet need, driving the development of novel therapies like fusion proteins and antibody-oligonucleotide conjugates specifically engineered to actively cross the BBB. Companies are leveraging proprietary transport platforms to ensure therapeutic enzymes reach neuronal lysosomes, which is essential for preventing cognitive decline and neurological motor dysfunction. Highlighting progress in this area, JCR Pharmaceuticals announced in February 2025, during its press release 'Research Presentations at WORLDSymposium(TM) 2025 Showcase Research', the unveiling of new datasets demonstrating the capability of its proprietary J-Brain Cargo technology to successfully deliver therapeutic enzymes across the blood-brain barrier for lysosomal storage disorders.

Key Market Players

  • Genzyme Corporation
  • Amicus Therapeutics Inc
  • Valerion Therapeutics LLC
  • Audentes Therapeutics Inc
  • Actus Therapeutics Inc
  • BioMarin Pharmaceutical Inc
  • EpiVax inc
  • Oxyrane Co Ltd.
  • Sangamo BioSciences Inc
  • Avrobio Inc
  • Spark Therapeutics Inc

Report Scope

In this report, the Global Pompe Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pompe Disease Therapeutics Market, By Treatment Type

  • Drugs
  • Enzyme Replacement Therapy
  • Physical Therapy
  • Chaperone-Advanced Replacement Therapy

Pompe Disease Therapeutics Market, By Route of Administration

  • Oral
  • Parenteral

Pompe Disease Therapeutics Market, By End User

  • Hospitals & Speciality Clinics
  • Other

Pompe Disease Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pompe Disease Therapeutics Market.

Available Customizations:

Global Pompe Disease Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pompe Disease Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Drugs, Enzyme Replacement Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy)
    • 5.2.2. By Route of Administration (Oral, Parenteral)
    • 5.2.3. By End User (Hospitals & Speciality Clinics, Other)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pompe Disease Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pompe Disease Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Pompe Disease Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Pompe Disease Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By End User

7. Europe Pompe Disease Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pompe Disease Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By End User
    • 7.3.2. France Pompe Disease Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Pompe Disease Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Pompe Disease Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Pompe Disease Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By End User

8. Asia Pacific Pompe Disease Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pompe Disease Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By End User
    • 8.3.2. India Pompe Disease Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Pompe Disease Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Pompe Disease Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Pompe Disease Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By End User

9. Middle East & Africa Pompe Disease Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pompe Disease Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Pompe Disease Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Pompe Disease Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By End User

10. South America Pompe Disease Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pompe Disease Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Pompe Disease Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Pompe Disease Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pompe Disease Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Genzyme Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Amicus Therapeutics Inc
  • 15.3. Valerion Therapeutics LLC
  • 15.4. Audentes Therapeutics Inc
  • 15.5. Actus Therapeutics Inc
  • 15.6. BioMarin Pharmaceutical Inc
  • 15.7. EpiVax inc
  • 15.8. Oxyrane Co Ltd.
  • 15.9. Sangamo BioSciences Inc
  • 15.10. Avrobio Inc
  • 15.11. Spark Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer